載入...
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
In non-small cell lung cancer (NSCLC), the most frequent oncogenic mutation in western countries is KRAS, for which, however, there remains no clinically approved targeted therapies. Recent progress on high biological heterogeneity including diverse KRAS point mutations, varying dependence on mutant...
Na minha lista:
| 發表在: | Front Oncol |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Frontiers Media S.A.
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6773824/ https://ncbi.nlm.nih.gov/pubmed/31612108 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00953 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|